include venous stasis, pelvic venous compression by the gravid uterus, pulsatile compression of the left iliac vein by the right iliac artery and changes in pro-and anticoagulant and fibrinolytic pathways. [5] [6] [7] [8] For example, plasma endogenous thrombin potential and plasminogen activator inhibitor-1 levels are significantly higher in pregnant women compared with nonpregnant controls. 7, 8 In pregnancy, platelets undergo morphological changes and their activation is increased. 9 Upon activation, platelets release a multitude of signaling (soluble and vesicular) factors collectively termed the platelet releasate (PR), 10 which plays important roles in hemostasis, wound healing, and inflammatory response. 11 Maternal PR enhances trophoblast invasion and drives placental bed angiogenesis, critical processes during normal placentation. 12 Recently, PR contents of 18 healthy pregnant and 13 nonpregnant women were characterized using comparative label-free quantitative proteomic profiling and shown to be altered in pregnant compared with nonpregnant women. 13 Sixty-nine PR proteins were differentially released, and 11 PR proteins were capable of discriminating pregnant and nonpregnant women with an area under the curve of 0.876, sensitivity of 88.9%, and specificity of 84.6%. It remains to be determined whether this change in PR contents contributes to pregnancy-associated VTE (PA-VTE) risk.
| ISTH 2019 (Melbourne) report
De Laurenzo and colleagues 14 evaluated thromboelastography parameters in 70 healthy pregnant or postpartum women, reporting a lower "K" parameter and higher "alpha angle" and "maximum amplitude (MA)" parameters in the first trimester compared with the postpartum period, overall suggesting a prothrombotic state using this assay in the postpartum period. Another multicenter cross-sectional cohort study by Obeng-Tuudah and colleagues including 175 women showed that platelet function (measured by light transmission aggregometry in response to 6 agonists) demonstrated a non-statistically significant increase with advancing pregnancy, reaching highest levels in the third trimester and reverting to control levels postpartum. 15 
| ADDITIONAL PA-VTE RISK FACTORS
This elevated baseline PA-VTE risk is further increased by additional maternal, pregnancy, and delivery characteristics (Table 1) , 5, [16] [17] [18] [19] [20] [21] [22] [23] highlighting the importance of VTE risk assessment in early pregnancy, at delivery, and throughout pregnancy if risk factors change (eg, during extended antenatal immobilization, as will be discussed later). 24 
| Thrombophilia
PA-VTE risk is higher in women with inherited and acquired thrombophilia compared with those without these conditions, particularly if associated with a family history of VTE. [25] [26] [27] [28] The reported increase in PA-VTE risk varies widely depending on the type of thrombophilia and between studies. The American Society of Hematology (ASH) guideline panel has suggested that the appropriate threshold for initiation of thromboprophylaxis during pregnancy is approximately 2%. 25 Absolute risks of VTE during pregnancy appear not to reach this threshold in the case of some thrombophilias but do with others.
For example, in a recent case-control study, the absolute reported TA B L E 1 aOR and IRR reported for selected maternal, pregnancy, and delivery characteristics in the listed studies Note: The reported strength of these characteristics is highly variable between studies: the intention of this table is to raise awareness of the need to consider individualized risk assessment at these times in the pregnancy journey rather than to comprehensively review all reported risk factors.
Abbreviations: aOR, adjusted odds ratio; ART, assisted reproductive technology; BMI, body mass index; CI, confidence interval; CS, cesarean section; FHx, family history of VTE; IRR, incidence rate ratio; IUGR, intrauterine growth restriction; PPH, postpartum haemorrhage; VD, vaginal delivery. a As a predictor of antenatal VTE events. risk of PA-VTE in women heterozygous for the factor V Leiden (FVL) polymorphism was 0.5% (95% CI, 0.23%-0.72%) in women aged <35 years 28 
| How frequently do PA-VTE risk factors occur?
VTE risk factors vary in their association with PA-VTE risk but appear to be common. In a recently published cross-sectional study of prospectively collected data from 21 019 sequential postpartum VTE risk assessments completed over a 3-year period in the Rotunda Hospital, Dublin, Ireland, the most common VTE risk factors related to maternal characteristics and delivery characteristics included overweight and obesity (36%), age ≥ 35 (35%) and cesarean delivery (32%). Over three-quarters of women had at least 1 VTE risk factor (78%), and over 40% had multiple (2 or more) VTE risk factors. In 19% of women, all VTE risk developed during delivery or in the postpartum period (and were not present prior to the peripartum period; Figure 1 ), 36 highlighting the critical importance of performing VTE risk assessment after delivery.
| REDUCING THE RISK OF VTE IN PREGNANCY
Addressing the question "does pharmacological thromboprophylaxis reduce the risk of PA-VTE" has been challenging, despite some progress in specific areas, which will be discussed. Indeed, the authors of a 2014 Cochrane review concluded that "there is insufficient evidence on which to base recommendations for thromboprophylaxis during pregnancy (and that) large scale, high-quality randomised trials of currently used interventions are warranted." 37 However, the experience of the PROSPER investigators has dem- 39 Of 343 eligible women, only 37 were randomized over 4.9 months, with an overall recruitment rate of 0.9 per center per month. The authors noted that "poor recruitment is a common and major threat to the completion of RCTs, especially notable in the peri-partum population."
Consequently, to date, guideline recommendations are mainly based on expert opinion rather than high-quality evidence. 24, 25, [40] [41] [42] This can be extremely difficult for care providers, particularly given the competing risks and challenges of pharmacological thromboprophylaxis, which are relatively common 43 and include bleeding, bruising, skin reactions, pain, and, in many jurisdictions, high out-ofpocket costs.
| What is the effect of LMWH on bleeding risk during pregnancy?
Despite the fact that the stakes are so high, there is a dearth of high-quality data surrounding the impact of LMWH on bleeding risk during pregnancy. A 2005 systematic review that aimed to assess the safety and efficacy of LMWH during pregnancy reported a 2.0% (95% CI, 1.50%-2.61%) overall risk of "significant maternal bleeding" for women receiving LMWH for thromboprophylaxis, adverse pregnancy outcome, or unspecified indications. 43 These events included antenatal bleeding (0.42%; 95% CI, 0.21%-0.75%), "primary obstetric causes" for bleeding (0.92%; 95% CI, 0.59%-1.37%), and wound hematoma (0.65%; 95% CI, 0.38%-1.04%).
There is frequently no consistent definition of bleeding in studies antepartum and postpartum thromboprophylaxis ( Figure 2 ).
25,40
These recommendations reflect lower reported recurrence risks for women with provoked (nonhormonal) VTE than for women whose VTE was estrogen related or unprovoked: In a pooled analysis of 4 cohort studies, major antenatal VTE recurrence rates without prophylaxis were 1.1% (95% CI, 0.2%-5.8%) 6.4% (95% CI, 3.9%-10.4%) and 3.6% (95% CI, 1.4%-8.9%) for these 3 groups, respectively. 
| ISTH 2019 (Melbourne) report
Interim data from the Highlow RCT on obstetric outcome and anesthetic use in 541 women using antepartum LMWH were presented by Dr Bistervels on behalf of the Highlow investigators. 45 95% CI, 0.7-1.4).
F I G U R E 2
Prevention of VTE in women with prior VTE or thrombophilia. Guideline recommendations around VTE and thrombophilia can be broadly summarized as follows: Antepartum + postpartum thromboprophylaxis is recommended for women with prior unprovoked VTE or VTE provoked by estrogen or pregnancy (A) and for some strong thrombophilias, particularly if associated with a family history of VTE (B) due to a higher predicted recurrence risk than for women with a VTE provoked by major transient nonhormonal provoking factors and some weaker thrombophilias, for whom only postnatal thromboprophylaxis is recommended (C 24, 25, 40, 41, 47 However, a consistent theme is the suggestion for implementation of ante-and postpartum thromboprophylaxis in pregnant women with "high-risk" thrombophilias, especially when accompanied by a strong family history (Figure 2) , in which the predicted absolute VTE risk is above the ~2% threshold accepted in recent international guidelines but not for "lowrisk" thrombophilias (eg, those associated with a <1% absolute predicted VTE risk). 25 
| PA-VTE risk reduction in women with multiple, common VTE risk factors
Although arguably the best-quality data exist to address PA-VTE risk reduction in women with a personal VTE history or inherited thrombophilia, these 2 categories of risk factor are rare (<1% in a recent large prospective study.
36
) The optimal strategy for PA-VTE prevention in women with more common VTE risk factors remains a critical knowledge gap, as evidenced (again) by widely varying international guideline recommendations 24, 25, 40, 47, 48 and intense debate. 49, 50 In particular, the balance of thrombosis and bleeding risk is uncertain, and it is noteworthy that the 2018 ASH guideline panel highlighted important research needs, including a requirement for more data on the absolute VTE risk in women with combinations of known risk factors. 25 Reflecting the lack of data, we recently performed an analysis of prospectively collected data from 21 019 consecutive comprehensive postpartum VTE risk assessments, applying Postpartum hemorrhage was recorded in 3.2% of women before and 4.5% after implementation (RR, 1.38; 95% CI, 0.89-2.13; P = 0.15).
| ISTH 2019 (Melbourne) report
Dr O'Shaughnessy of the Rotunda Hospital, Dublin, Ireland, presented pilot data evaluating the impact of systematic electronic VTE risk assessment 52 in all postpartum women combined with a strong positive campaign to increase VTE awareness among multidisciplinary colleagues on VTE prevention strategies in a large maternity hospital. 53 Introduction of these measures resulted in an increase in use of riskappropriate pharmacological thromboprophylaxis (RA-TPX) from 68%
to 89% (P < 0.001). This was primarily driven by increased use of RA-TPX after vaginal delivery (10%-72%) following the introduction of this tool (P < .001). Moreover, in this preliminary sample, hospital-level VTE events recorded at the institution during the delivery admission or in the postpartum period reduced from 22 (0.08%) in the 3-year period before introduction of "Thrombocalc" to 4 (0.02%) in the 3-year period after introduction of Thrombocalc (RR, 0.19; 95% CI, 0.07-0.56; P < 0.001), with the caveat that these VTE events were not adjudicated.
In 
| VTE AWARENESS DURING PREGNANCY AND THE IMPORTANCE OF RISK ASSESSMENT
The international World Thrombosis Day campaign (https ://www.
world throm bosis day.org/; @thrombosisday) aims to increase awareness of thrombosis and prevent death and disability due to this condition. This is highly relevant for pregnant women, their families, and their care providers. In a recent review of international guidelines on PA-VTE, 8 of 9 guidelines assessed recommended that all women should also undergo VTE risk factor assessment. which showed that knowledge of VTE was very low among pregnant women in Kigali, with only 9.33% and 15.7%, respectively, having "good knowledge" of VTE and treatment options respectively. 57 
| KNOWLEDGE GAPS
• Optimal LMWH dose for prevention of VTE recurrence in women with prior VTE
• Validation of clinical prediction tools evaluating absolute risk of VTE during antepartum and postpartum periods
• Optimal risk threshold for initiating pharmacological thromboprophylaxis in the antepartum and postpartum periods, particularly in women with lower-risk thrombophilic traits and multiple (common) VTE risk factors.
• Optimal duration of pharmacological thromboprophylaxis in the postpartum period
• Absolute bleeding risks and type of bleeding with pharmacologic thromboprophylaxis (eg, incisional versus uterine bleeding).
| CONCLUSIONS
Pregnancy-associated VTE can be a devastating event, with significant associated morbidity and mortality. Knowledge and awareness of VTE risk factors is vital to ensure that appropriate risk-reduction measures are implemented. Well-designed studies are ongoing and are likely to address important research questions in specific areas.
However, important knowledge gaps remain, and these research areas should be prioritized to protect the health and lives of pregnant and postpartum women.
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